Dealroom
Cover art for VitriVax raises $87M for Lyme vaccine

VitriVax raises $87M for Lyme vaccine

VitriVax secures $87 million Series C funding to develop first Lyme disease vaccine.

Nov 18, 2026

2 cards · 30s · tap to begin

From · · 30s

VitriVax raises $87M for Lyme vaccine

VitriVax secures $87 million Series C funding to develop first Lyme disease vaccine.

In brief

VitriVax secures $87 million Series C funding to develop first Lyme disease vaccine. VitriVax raised $87 million Series C to pursue Lyme disease vaccine after no approved human vaccine exists. Originally reported by Dealroom.

Funding round

VitriVax raised $87 million Series C to develop Lyme disease vaccine.

Market gap

No approved human Lyme vaccine exists, creating unmet need for new solution.

The bottom line

VitriVax raised $87 million Series C to pursue Lyme disease vaccine after no approved human vaccine exists.

Read the original on Dealroom

Read the TL;DR — this story on one card.

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on vitrivax and related topics.